Following on from information provided to NICE by the company in April 2022, the appraisal of Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 3999

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
02 May 2023 Discontinued. Following on from information provided to NICE by the company in April 2022, the appraisal of Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

For further information on our processes and methods, please see our CHTE processes and methods manual